![if gte IE 9]> <![endif]>
A therapy for patients with a type of skin cancercalled cutaneous squamous cell carcinoma (CSCC) that has spread or cannot be cured by surgery or radiation
LIBTAYO was studied in 2 clinical trials in patients with CSCC that had spread or could not be cured by surgery or radiation.
In 1 clinical trial, 47% (91 out of 193) of patients* saw an improvement in their advanced CSCC. In the same clinical trial, in a subset of patients with CSCC that had spread who took LIBTAYO at the recommended dose,† 46% (26 out of 56) of patients saw an improvement in their advanced CSCC.
In this trial, responses lasted between 1.9 months and more than 4 years (54.6 months).
View full clinical trial results
Learn more about how CSCC can become advanced.Read more